Refractory, advanced Mycosis fungoides Recruiting Phase 1 / 2 Trials for Durvalumab (DB11714)

Also known as: Refractory advanced Mycosis fungoides / Mycosis fungoides refractory / Refractory Mycosis Fungoides

IndicationStatusPhase
DBCOND0024424 (Refractory, advanced Mycosis fungoides)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03011814Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaTreatment